



Date of submission: May 23, 2025

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code –539551(EQ), 975516 & 976418	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH
--	--

Dear Sir/Madam,

Sub: Press Release for the quarter and financial year ended March 31, 2025 and Call invite

With reference to the subject, please find enclosed the Press Release for the quarter and financial year ended March 31, 2025.

Further to our letter dated May 19, 2025, also please find attached the call invite to discuss the Company's performance on **Tuesday, May 27, 2025 at 03:00 P.M. (IST)**.

Kindly take the above information on record.

Thanking you

Yours faithfully
For **Narayana Hrudayalaya Limited**

Sridhar S.
Group Company Secretary, Legal & Compliance Officer

Encl.: as above

PRESS RELEASE – Q4 FY25 and FY25 Results

Q4 FY25 Consolidated operating revenue at ₹ 14,754 Mns (YoY growth of 18.4%) with EBITDA of ₹ 3,846 Mns (YoY growth of 22.2%)
FY25 Consolidated operating revenue at ₹ 54,830 Mns (YoY growth of 12.1%) with EBITDA of ₹ 13,684 Mns (YoY growth of 11.9%)

Bengaluru, India, May 23rd, 2025 – Narayana Hrudayalaya Limited, a leading healthcare service provider in India, announced its financial results for the fourth quarter (Q4 FY25) ended March 31st, 2025.

₹ Mns	Q4FY25	Q4FY24	YoY %	FY25	FY24	YoY%
India Revenue*	11,088	10,020	10.7%	43,499	39,085	11.3%
Cayman Revenue**	3,797	2,528	50.2%	11,829	10,261	15.3%
Consol Revenue***	14,754	12,462	18.4%	54,830	48,902	12.1%
Consol EBITDA	3,846	3,148	22.2%	13,684	12,224	11.9%
EBITDA margin	26.1%	25.3%		25.0%	25.0%	
PAT	1,962	1,880	4.4%	7,898	7,860	0.5%
PAT %	13.3%	15.1%		14.4%	16.1%	

* India and Consolidated numbers are adjusted with NVDSHPL.

**Cayman nos. are converted from USD to INR at 84.57 for FY25, and 82.79 for FY24. The numbers may slightly vary on conversion due to different exchange rates applicable at different reporting period.

*** Consol revenue numbers are adjusted for Inter-company eliminations.

Financial Highlights for the Quarter (Q4 FY25) - Prepared in accordance with Ind AS ('Indian Accounting Standards')

- Consolidated total operating revenue was ₹ 14,754 Mns for Q4 FY25 as compared to ₹ 12,462 Mns in the corresponding period of the previous year, reflecting a change of +18.4 % YoY and +10.6% QoQ.
- Consolidated EBITDA stood at ₹ 3,846 Mns, reflecting a margin of 26.1% as against ₹ 3,148 Mns in Q4 FY24, translating into a change of +22.2% YoY and +18.1% QoQ.
- Consolidated PAT stood at ₹ 1,962 Mns, reflecting a margin of 13.3% as compared to ₹ 1,880 Mns in Q4 FY24, translating into a change of +4.4% YoY and +1.3% QoQ.
- India operating revenue was ₹ 11,088 Mns for Q4 FY25 as compared to ₹ 10,020 Mns in the corresponding period of the previous year, reflecting a change of +10.7% YoY and +5.1% QoQ.
- Cayman operating revenue was ₹ 3,797 Mns for Q4 FY25 as compared to ₹ 2,528 Mns in the corresponding period of the previous year, reflecting a change of +50.2% YoY and +29.4% QoQ.

Financial Highlights for the Twelve Months (FY25) - Prepared in accordance with Ind AS ('Indian Accounting Standards')

- Consolidated total operating revenue was ₹ 54,830 Mns for FY25 as compared to ₹ 48,902 Mns in FY24, reflecting a change of +12.1%.
- Consolidated EBITDA stood at ₹ 13,684 Mns for FY25, reflecting a margin of 25.0% as against ₹ 12,224 Mns in FY24, translating a change of +11.9%.
- Consolidated PAT stood at ₹ 7,898 Mns for FY25, reflecting a margin of 14.4% as compared to ₹ 7,860 Mns in FY24.
- India operating revenue was ₹ 43,499 Mns for FY25 as compared to ₹ 39,085 Mns in FY24, reflecting a change of +11.3%.
- Cayman operating revenue was ₹ 11,829 Mns for FY25 as compared to ₹ 10,261 Mns in FY24, reflecting a change of +15.3%.

As on March 31st, 2025, the Total Borrowings less Cash & Bank Balance and Investments was INR 5,330 Mns, representing a net debt to equity ratio of 0.15 (Out of which, debt worth US\$ 86.8 Mns is foreign currency denominated).

Other Highlights during the Quarter

- **Narayana Health Group** has successfully performed the following procedures:
 - 1200+ Robot-Assisted Surgical procedures in FY25
 - 332 Robotic Cardiac Surgery in FY25
 - 380+ Robotic Procedures in Q4FY25
- **Narayana Institute of Cardiac Sciences (NICS), Bengaluru** has performed the following procedures during the quarter:
 - 301 Minimally Invasive Cardiac Surgical Procedures
 - 40 Transcatheter Aortic Valve Implantation (TAVI)
- **Narayana Health SRCC Children's Hospital, Mumbai** has reached a milestone of 100 Epilepsy Surgeries in the quarter, a feat achieved in a short span of 2.5 years
- **MMI Narayana Hospital, Raipur** has achieved the milestone of 3000+ patients in Radiation Oncology in Q4 FY25.

Management Comment

Commenting on the performance, **Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited**, said "The current financial year demonstrated strong performance across our units both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both quarterly as well as annual basis at the consolidated level. The performance improvement in India units has been driven by domestic volume pickup, increased realizations, and optimization in payor categories. While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. HCCI continues to contribute significantly, delivering record revenues on both quarterly and annual basis. The new hospital in Camana Bay is fully functional and is contributing meaningfully to the overall Cayman business. We are excited with the traction in the new hospital and are confident that the region will deliver strong growth going forward. The Integrated Care business is picking up well, with our new clinics garnering sizeable footfalls. We will continue to invest in this business and are optimistic that it will be a significant driver of growth to the overall NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year."

About Narayana Hrudayalaya Limited

Founded in 2000 by Dr. Devi Prasad Shetty and headquartered in Bengaluru, Narayana Hrudayalaya Limited is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The Company has a network of 18 hospitals and 2 heart centers across India along with overseas presence at Cayman Islands, with over 5,550 operational beds and a capacity of over 5,900 beds.

For further details, please contact:

Nishant Singh
nishant.singh@narayanahealth.org
+91.8369353821

Vivek Agarwal
vivek.agarwal@narayanahealth.org
+91.9510756827

investorrelations@narayanahealth.org

Important Disclaimer

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.

Q4 FY25 and FY25 Result Conference Call

At 03:00 PM, IST on May 27th, 2025

Following the announcement of the fourth quarter (Q4 FY25) ended March 31st, 2025, results on May 23rd, 2025, the management of Narayana Hrudayalaya Limited will host a conference call to discuss the Company's performance on May 27th, 2025, at 03:00 pm IST.

Date:	Tuesday, May 27 th , 2025										
Time:	03:00 pm IST										
Zoom Dial-in Details:											
Details of Conference call	<div>Click here to Join the Conference Call</div> <p>Meeting ID: 890 8923 7140</p> <p>Passcode: 736807</p> <p><u>Conference dial-in by your location</u></p> <table><tr><td>US</td><td>▪ +1 646 931 3860</td></tr><tr><td>Singapore</td><td>▪ +65 3129 4892</td></tr><tr><td>Mexico</td><td>▪ +52 558 659 6002</td></tr><tr><td>Russia</td><td>▪ +7 499 951 6380</td></tr><tr><td>Japan</td><td>▪ +81 3 4579 0545</td></tr></table>	US	▪ +1 646 931 3860	Singapore	▪ +65 3129 4892	Mexico	▪ +52 558 659 6002	Russia	▪ +7 499 951 6380	Japan	▪ +81 3 4579 0545
US	▪ +1 646 931 3860										
Singapore	▪ +65 3129 4892										
Mexico	▪ +52 558 659 6002										
Russia	▪ +7 499 951 6380										
Japan	▪ +81 3 4579 0545										
Transcript	The transcript will be uploaded on our website www.narayanahealth.org										